R&D Towards better quality of life, GNT Pharma


Global New Drug Development Pipeline

CRISDESALAZINE Crisdesalazine / Drug for Alzheimer’s disease (AD)

  • Drag from side to side.

  • Crisdesalazine is a multi-target drug that removes both free radicals and inflammation, which are proven contributors to Alzheimer’s disease and other neurodegenerative brain diseases.
  • Pharmacological action: (1) next-generation anti-inflammatory effect through inhibition of mPGES-1; (2) Remove free radicals (antioxidant)
  • Safety and anti-inflammatory effects are substantially improved with few adverse drug effects compared to nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Demonstration of efficacy in animal models of neurodegenerative diseases.
  • Significant inhibition of ATN (A: Amyloidopathy, T: Tauopathy, N: Neurodegeneration), important pathological and diagnostic markers of AD in cultured cells and mouse models of dementia.
  • Demonstration of improvement in cognitive function in pet dogs with canine cognitive dysfunction syndrome, a canine disease with strong clinical and pathological parallels to human Alzheimer’s disease.
  • Alzheimer’s Disease
  • Amyotrophic Lateral Sclerosis
  • Parkinson’s Disease
  • Spinal Muscular Atrophy
  • Depression
Comparison of Crisdesalazine and current drugs for Alzheimer’s Disease patients
  • Drag from side to side.

Crisdesalazine (AAD-2004) Investigational Drugs donepezil memantine
Mode of Action mPGES-1 inhibition1+spin trapping anti-oxidant
  • Anti-oxidant
  • NSAIDs
  • Anti-Beta amyloid drugs
acetylcholine esterase inhibition NMDA receptor antagonist
Efficacy In AD Models APP/PS1 mouse
  • Improves cognition at early to severe stage
  • Reduces beta amyloid
  • Prevents BBB damage
  • Improves cognition
  • Reduces beta amyloid
  • Improves cognition
  • Reduces beta amyloid
  • Improves cognition
  • Reduces beta amyloid
betaCTF99 mouse2,3
  • Prevents neuronal death
  • Prevents neuritic atrophy
(Not Determined)
GiDs mouse4
  • Prevents reactive astrocytes
  • Prevents neuronal death
  • Improves cognitive function
3D AD Cell Cultures4
  • Prevents reactive astrocytes
  • Prevents neuronal death
  • Prevents tauopathy
(Similar to Alzheimer’s disease)
  • Improves cognitive function
  • Slows disease progression
ND Improves cognition ND
Drug Development Stage Approved for CCDS
(Feb 2021)
(amyloid vaccine)
Conditional Approval
Approved for AD
Approved for AD
Related Articles